Investors

FGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$28.05
Change (%)0.00 (0.00%)
Volume0
Data as of 04/27/17 4:00 p.m. ET
Refresh quote
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.
Recent Press ReleasesMore »
DateTitle 
04/06/17FibroGen, Inc. Announces Pricing of Follow-On Offering of Common StockPrinter Friendly Version
03/31/17FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDSPrinter Friendly Version
03/30/17Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney DiseasePrinter Friendly Version
03/01/17FibroGen Reports Fiscal 2016 Financial ResultsPrinter Friendly Version
Upcoming EventsMore »
DateTitle
06/07/17 8:00 a.m. PT
FibroGen Inc 2017 Annual Stockholder Meeting
LocationFibroGen, Inc. Headquarters
409 Illinois Street
San Francisco, CA 94158
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources